[PDF][PDF] 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

P Kirchhof, S Benussi, D Kotecha… - Polish Heart …, 2016 - journals.viamedica.pl
Komisję ESC ds. Wytycznych Postępowania nadzoruje i koordynuje przygotowywanie
nowych wytycznych i stanowisk przez grupy robocze i inne grupy ekspertów. Komitet jest …

[HTML][HTML] Estándares SEA 2019 para el control global del riesgo cardiovascular

JM Mostaza, X Pintó, P Armario, L Masana… - Clínica e Investigación …, 2019 - Elsevier
Resumen La Sociedad Española de Arteriosclerosis tiene entre sus objetivos contribuir al
mayor y mejor conocimiento de la enfermedad vascular, su prevención y su tratamiento. Las …

[PDF][PDF] 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

F Casselman, A Coca, R De Caterina… - European heart …, 2016 - academia.edu
Surveys and registries are needed to verify that real-life daily practice is in keeping with what
is recommended in the guidelines, thus completing the loop between clinical research …

Experimental drugs for supraventricular tachycardia: an analysis of early phase clinical trials

B Narasimhan, K Gandhi, E Moras, L Wu… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Supraventricular tachycardias (SVT) are a diverse group of commonly
encountered arrhythmias arising at or above the atrioventricular (AV) node. Conventional …

[PDF][PDF] Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS

S Benussi, D Kotecha, A Ahlsson… - Rev Esp …, 2017 - sedeelectronica.comcordoba.com
Se recomienda a los profesionales de la salud que tengan en consideración la presente
guía de la ESC/EACTS en la toma de decisiones clínicas en su ejercicio diario, así como en …

Plasma omega‐3 fatty acids and the risk of cardiovascular events in patients after an acute coronary syndrome in MERLIN‐TIMI 36

TA Zelniker, DA Morrow, BM Scirica… - Journal of the …, 2021 - Am Heart Assoc
Background Plasma omega‐3 polyunsaturated fatty acids (ω3‐PUFAs) have been shown to
be inversely correlated with the risk of cardiovascular death in primary prevention. The risk …

[HTML][HTML] Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives

F De Sensi, T De Potter, A Cresti, S Severi… - Cardiovascular …, 2015 - ncbi.nlm.nih.gov
Atrial fibrillation (AF) remains the most frequent sustained cardiac arrhythmia worldwide and
its incidence increases with ageing, cardiovascular risk factors and comorbidities …

Ranolazine: An old drug with emerging potential; lessons from pre-clinical and clinical investigations for possible repositioning

S Rouhana, A Virsolvy, N Fares, S Richard, J Thireau - Pharmaceuticals, 2021 - mdpi.com
Ischemic heart disease is a significant public health problem with high mortality and
morbidity. Extensive scientific investigations from basic sciences to clinics revealed …

Antiarrhythmic properties of ranolazine: a review of the current evidence

T Gupta, S Khera, D Kolte, WS Aronow… - International journal of …, 2015 - Elsevier
Ranolazine was developed as an antianginal agent and was approved by the Food and
Drug Administration in 2006 for use in chronic stable angina pectoris. Experimental and …

Ranolazine for rhythm control in atrial fibrillation: a systematic review and meta-analysis

F Guerra, A Romandini, A Barbarossa… - International Journal of …, 2017 - Elsevier
Background/objectives Available pharmacological options for rhythm control strategy in
atrial fibrillation (AF) are limited by sub-optimal efficacy and potentially serious adverse …